Molecular response to imatinib in patient with Ph negative p190 BCR–ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis
✍ Scribed by M. Radojkovic; S. Ristic; S. Pavlovic; M. Colovic
- Book ID
- 104040895
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 181 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
✦ Synopsis
An atypical case of Philadelphia (Ph) negative, e1a2 BCR-ABL transcript positive chronic myeloid leukemia (CML) characterized with cyclic periodic leukocytosis and spontaneous remissions is reported. The patient was treated with imatinib and good hematology response with molecular remission was achieved. So far, only few Ph positive CML patients expressing p190 BCR-ABL protein and different clinical characteristics and treatment have been described in the literature. This is the first report of Philadelphia negative, p190 BCR-ABL positive CML with cyclic spontaneous oscillation of white blood cell count (WBC), and excellent response to imatinib treatment.
📜 SIMILAR VOLUMES
Since very few unusual BCR/ABL fusion transcripts in chronic myeloid leukemia have been reported, no clear evidence exists concerning their clinical and prognostic implications. We describe here a CML case with normal karyotype at standard cytogenetics and an atypical e6a2 BCR/ABL fusion transcript,
## Abstract Leukemic cells from two patients with Philadelphia‐negative chronic myeloid leukemia (CML) were investigated: I) Cytogenetics showed a normal 46.XY karyotype in both cases, 2) molecular studies revealed rearrangement of the M‐BCR region and formation of __BCR‐ABL__ fusion mRNA with b2a2